Data and tools
Children's Social Care data in England 2019: This statistical release provides inspection data and information about the providers and places of children’s social care in England and the outcomes of inspection for local authority children’s services. The data released shows that the overall effective profile of local authorities has improved and while the number of local authority run homes continues to decrease, four in five children’s homes are judged good or outstanding, slightly less than the previous year.
Childhood Vaccination Coverage Statistics: This statistical report reports on the coverage of childhood vaccination (up to five years of age) for England in 2019-20. Overall, data showed that coverage increased in most routine vaccinations. It showed an increase in MMR1 coverage at 24 months for the first time since a peak in 2013-14. The 5-in-1 coverage at 5 years also remained above the 95% target. The data is also available in the form of an interactive dashboard.
The hidden impact of COVID-19: This is a series of global research analysis published by Save the Children with over 13,500 children and 31,500 caregivers from 46 countries. Globally, 8 in 10 children felt they were learning little or nothing at all, 75% of households lost income, 95% of households reported having trouble paying for an essential item/service and 89% reported that their access to healthcare, medicines or medical supplies had been affected. Results also showed a significant negative impact on the psycho-social wellbeing of children and caregivers. Vulnerable households including the poorest, those with disabilities and girls were disproportionately affected. The outlined recommendations to build back post COVID-19 are guided by the voices of children.
The Promise of Adolescence: Adolescence is critical for development during which key areas of the brain mature and develop. It is crucial that countries implement policy and practice that leverage these developmental opportunities to harness the promise of adolescence as opposed to focusing on containing its risks. This report examines the neurobiological and socio-behavioural science of adolescent development and outlines how this knowledge can be applied to promote adolescent health and well-being, resilience and development and to correct structural barriers and inequalities in opportunity.
Early Gluten Introduction and Celiac Disease in the EAT Study: The authors aimed to study whether the early introduction of high dose gluten lowers the prevalence of celiac disease through the Enquiring About Tolerance (EAT) Study, an open-label randomized clinical trial. Infants were either randomized to consume 6 allergenic foods in addition to breast milk from 4 months or to avoid these foods and follow exclusive breastfeeding until 6 months. Between 4 and 6 months, infants in the intervention group consumed 2.66/wk of gluten compared to 0.49g/wk, and significantly more children in the control group had a diagnosis of celiac disease (1.4% vs 0%). These findings suggest that early high-dose consumption of gluten should be considered as a strategy to prevent celiac disease in future studies.
High-dose and low-dose varenicline for smoking cessation in adolescents: While smoking tends to begin in adolescence, evidence on successful pharmacological smoking cessation is limited in this population group. The study aimed to assess the efficacy and tolerability of varenicline for smoking cessation in adolescents aged 12-19 using a randomised, placebo-controlled trial at 57 outpatient centres across 6 countries. Participants were either randomly assigned to placebo, a high dose or a low dose of varenicline. Findings showed that abstinence rates between high-dose varenicline and placebo and between low-dose varenicline and placebo groups did not differ significantly, thus not in favour of supporting the use of varenicline as a first-line pharmacotherapy for smoking cessations in adolescents.